{"name":"Provention Bio, Inc.","slug":"provention-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Tzield first approved","drug":"Tzield","drugSlug":"teplizumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-12","label":"TZIELD Phase 3 readout (Type 1 Diabetes Mellitus)","drug":"TZIELD","drugSlug":"teplizumab-mzwv","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"TZIELD","genericName":"TEPLIZUMAB-MZWV","slug":"teplizumab-mzwv","indication":"Delay onset of Stage 3 type 1 diabetes","status":"marketed"},{"name":"Tzield","genericName":"TEPLIZUMAB","slug":"teplizumab","indication":"Diabetes mellitus type 1","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"PRV-015","genericName":"PRV-015","slug":"prv-015","indication":"Other","status":"phase_2"},{"name":"PRV-6527","genericName":"PRV-6527","slug":"prv-6527","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"TZIELD","genericName":"TEPLIZUMAB-MZWV","slug":"teplizumab-mzwv","phase":"marketed","mechanism":"T-cell surface glycoprotein CD3","indications":["Delay onset of Stage 3 type 1 diabetes"],"catalyst":""},{"name":"PRV-015","genericName":"PRV-015","slug":"prv-015","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"PRV-6527","genericName":"PRV-6527","slug":"prv-6527","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tzield","genericName":"TEPLIZUMAB","slug":"teplizumab","phase":"marketed","mechanism":"Tzield works by binding to the CD3 complex on T-cells, preventing them from attacking pancreatic beta cells.","indications":["Diabetes mellitus type 1"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPbUdkR21LVTZuQ0s5VVhvZXY0WktUNE4xWUNhZ25MWVRTVEktSng0U1pHNkJaRjFKTUxzdUxkTnlacDhjQjJtZ3N5Vnh1a29PTzh2WmZuQzFfU3pBekFMb0VvV2xycjBuMkV2Nk94ZEJlN2tIZDQ5ZG5KR1VoSWlmellUTHNsbHdpa1ZHTEZPejhCc2RsZ1JvcHgwcnVxQnpkOFd3WndGUnVNQQ?oc=5","date":"2023-03-16","type":"deal","source":"TechTarget","summary":"Sanofi Acquires Provention Bio for $2.9 Billion - TechTarget","headline":"Sanofi Acquires Provention Bio for $2.9 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9FMUN6S0dQQk5Zc3hJVVR2QnhYZk9neThpOTg2ekFNb09HWjdvZGtUOFNSSjdJWjRvcndrSEZNNlloMk1FYmszNER0bS1JdTJyNUg2SXpDZ1AtS0gyeUtjSFZ2azhHQkhldXRkOVZ4YzBncElKelhsUTlFMmZQUQ?oc=5","date":"2023-03-13","type":"deal","source":"Pharmaceutical Technology","summary":"Sanofi signs deal to buy Provention Bio for $2.9bn - Pharmaceutical Technology","headline":"Sanofi signs deal to buy Provention Bio for $2.9bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOOHloR1VlYWE2QWN2YzdsRTFndjhUamV3b1VIVmphY3pTWFV2TExqSEVWYmsxM2hPb09ZeVVuWVNzSTV2Y1JXWW5tZ0lEa0FLdDd2d2w0cmhUc0lEaGY2Q2IxR01GaDh3UEdDVURUam42WFM1TTI4TGFBVjVKby1Kd1cycjJ5YkJYVjBxNmV0ZWV3UHMzYVhBZWoxVTl4RUE3OG9ybnJn?oc=5","date":"2023-03-13","type":"deal","source":"Reuters","summary":"Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal - Reuters","headline":"Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMi1LNjF1TXFnYUFSRkRJTklTX25QeUJUQlhqSldIU0ptSmNMZVBhZE9jLWRlMzlnZVpDVmhJcDg2MXA5aS13aHFPQUo5ZDd2M0lUX0FYVU9xVDNhc3BvWVIzbk1qd2cxaHhRWTNRRFF2anltRFhNV19aUnJhWExIMWJ3UFpqMThI?oc=5","date":"2023-03-13","type":"pipeline","source":"Barron's","summary":"Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi - Barron's","headline":"Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxONGRNTmdFRkk3cnlNbC1DQ1BVbmdhSW1uSGVtWUNDejdZVmZQakxoekEzaDFuMXdINlk4WjQ4QkRCT0x2WmlXRmo5b0x2WHhndldLaDBLUlFnMEtsUkNzNVUtRnAzdU5WNmVpcEdWQ2VURHF0WGgzQ0lhMC1qV255ZWduc1FfbGpvTGhIdUNpR2E?oc=5","date":"2023-03-13","type":"deal","source":"BioPharma Dive","summary":"Sanofi acquires diabetes drug via Provention buyout - BioPharma Dive","headline":"Sanofi acquires diabetes drug via Provention buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNNGdGWmprMElRTjJPS1d4VzNYWV9WVzI5cUFiWlkzVnhSTHJ3c3BaUFgwRTdkZ3ZWQUJ5QXpnOVI4R1EwTjltVS1OY0lhY0RYOEUxU1FTTHJMVHVQTS1tWmxmWFJHT1Y2NEZ1ay1nd0Z2bWdud2c4bXZ3dlh1VmlJZ0JNempjWjJfUnAwZVBlWTBCSUZ3ZmJ2bUtYckJiTXllNmxGUzg5NWRWMUcyMjlpcHlabWNqVURmREhhQWtJTHNIYi0wLW8tOWxaYlVCbVNWN3dsSFN5akR4Z2wxOEhnT1p6MkQ?oc=5","date":"2023-03-13","type":"deal","source":"proactiveinvestors.com","summary":"Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal - proactiveinvestors.com","headline":"Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPam14cFpvc0tDcFFjMkdRTWd1Mm05X2ZDZEFFaF80ekIxeThlOVUwbm5tcnppRDJESTRCckIwWUFBcGhLOGtQVkhTM3ZVbDNVWXdhM2xBR3NxbVA5NFIzd0xFY2xWQnlMTTU3MHdpQU9ZN3J6UmRueW9qN1paR0FJN1g1TmZDNmNoaEtnSHdOc29lQUlhdUZVbzZGY21McmlvNDR4OTE3LVBIRzdNMHln?oc=5","date":"2023-02-22","type":"patent","source":"Seeking Alpha","summary":"Provention Bio: Good Prospects In T1D, But Patent Protection A Worry (PRVB) - Seeking Alpha","headline":"Provention Bio: Good Prospects In T1D, But Patent Protection A Worry (PRVB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQWW1acTVKbW9QVW1QNDU1RC1WVVZEblpxX1J0T3Y5cEF6VUttRVRYM2UyYVh4RkNNdmZuVEVhb1M2alNnY3Eyd0Jac0hIU0p6cmo4ZjZxcG9WVHp2andyd3VZQmVKQ1daTkltNXNtNFo0VUhYaTN5blJKWi0tcWhyelpZSUtqUkdjQXBfV3ZtZldHWEJsa1hYNUQ4cTdZRmZfNHhzTUdiOXhRRGM?oc=5","date":"2023-02-14","type":"pipeline","source":"Contract Pharma","summary":"Provention Bio Completes $35M Equity Investment from Sanofi US - Contract Pharma","headline":"Provention Bio Completes $35M Equity Investment from Sanofi US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPSU9sRVhrendNWTRMTG94aXF3UGoxWHBELXR1YXlkUEVRUHZCWUFaSmR6QUtHVUxpT2tnLUo5SE9hczhVdnc5Z3FQYk1KOVhmLWpRRDBtVmxKcHNzSERzMGZQMVY3bUFpZzVaaEtxQVhUczI5WlhRalg0ZHdWcTJmajBtNy1nYi1OcE9pSld4bzd4UnpuZ1pVRw?oc=5","date":"2023-01-06","type":"pipeline","source":"World Business Outlook","summary":"Provention Bio onboards Rita Jain, M.D., to Board of Directors - World Business Outlook","headline":"Provention Bio onboards Rita Jain, M.D., to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQVkREQzE2cEtPOUt6dnhvLXdUa1ZnRHRCYVNLWk1OZU1lRjlER0ppbTFsU2JBMmtBV0Q1SVlLSFRKaUhjVW9zS2tYR0dTMWJaQ2RLd0o1a2ZvR1U3VlJxNFRpMS1kV3ZMbnRVQXNJMkctaW5IUjdmN2xaRzBmNGc5Q0szSlpqeTFmTmlaZUVlQTgzWjg?oc=5","date":"2022-09-22","type":"pipeline","source":"The Motley Fool","summary":"1 Green Flag and 1 Red Flag for Provention Bio - The Motley Fool","headline":"1 Green Flag and 1 Red Flag for Provention Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNSTFuLXRqUkRVU0VZajNFeE5SMnFKdVRod3BQZTM4dFdabWRnLW9mLXppTGxvU2tYaDkyN3N6YjYxcjNrQWhtMTVqSEFHLVNJQTJfZ2xadWJ4aG9iREwwQ2J2NDRJaUNPZHZrMk1rQVBsTzIwN1pUbW5fUGVnc0dMS3B3bUI5OVFIZHNlVHhtelJOeUlPeldoT1lHZGVzV1dzUW9SeWpGNWdkME1KTGM1RjJNRG9hakNLV0V5S04xM1NaRTRVZ29MRU95Tjdqd3JPTXRReWN2NU52eXNaTnlwSlkxQkRIZkxucUFubDAyZFRhQ054V2FBYXFaMV9JODQ?oc=5","date":"2021-02-17","type":"deal","source":"PR Newswire","summary":"Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China - PR Newswire","headline":"Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOWF9IcmdCcGVfNUFGMGgwSzVYNVdKN0Etdm51Sy1qcm16Mm5XWEw0T1lza0RYVk1SMF9UMExTRURzbXlzRlVRMVA3WjZmU2dacS1jR2gtOV9SODFWUVpndmhPMGt4ZlBlckpET1ltWlItUm1rb2RDRnRtaUlzNkxqQ3BTTzBvQQ?oc=5","date":"2020-08-18","type":"pipeline","source":"marketscreener.com","summary":"Provention Bio, Inc.: Shareholders Board Members Managers and Company Profile | US74374N1028 - marketscreener.com","headline":"Provention Bio, Inc.: Shareholders Board Members Managers and Company Profile | US74374N1028","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_2":2},"enrichmentLevel":2,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}